an examination of the blue cross/blue shield biofeedback technology assessment report (tar) john d....

20
An Examination of the Blue Cross/Blue Shield Biofeedback Technology Assessment Report (TAR) John D. Perry, PhD AAPB Representative

Upload: kaylee-fitzgerald

Post on 26-Mar-2015

219 views

Category:

Documents


4 download

TRANSCRIPT

Page 1: An Examination of the Blue Cross/Blue Shield Biofeedback Technology Assessment Report (TAR) John D. Perry, PhD AAPB Representative

An Examination of the

Blue Cross/Blue Shield

Biofeedback Technology

Assessment Report (TAR)

John D. Perry, PhDAAPB Representative

Page 2: An Examination of the Blue Cross/Blue Shield Biofeedback Technology Assessment Report (TAR) John D. Perry, PhD AAPB Representative

Required Financial Disclosure

• Inventor of EMG vaginal sensor (1975); Quarter-century of personal investment

• Senior Fellow – Biofeedback Certification Institute of America (BCIA)

• Since 1994, 100% of my income has come from EMG Sensor royalties

• AAPB received a grant from Thought Technology Ltd. to cover my expenses

Page 3: An Examination of the Blue Cross/Blue Shield Biofeedback Technology Assessment Report (TAR) John D. Perry, PhD AAPB Representative

Overview

• Based on selective literature review

• Cited papers contradict TAR conclusion

• TAR’s academic objective is of debatable value in the real world

Page 4: An Examination of the Blue Cross/Blue Shield Biofeedback Technology Assessment Report (TAR) John D. Perry, PhD AAPB Representative

TAR’s Objective:

“...to determine whether adding biofeedback as an aid to performing pelvic muscle exercise results in a greater improvement in urinary incontinence, as compared to pelvic muscle exercises alone.”

Is Narrow (PME vs. PME+BFB) Compared with Broad PFES Objective:

“…to determine whether PFES improves health outcomes of patients with urinary incontinence.”

Page 5: An Examination of the Blue Cross/Blue Shield Biofeedback Technology Assessment Report (TAR) John D. Perry, PhD AAPB Representative

Is the TAR Objective Relevant?

• Continence therapy is typically staged, starting with PME and progressing to biofeedback

• HCFA’s present (regional) policies for biofeedback call for the exclusion of patients who have not yet failed PME Alone

Page 6: An Examination of the Blue Cross/Blue Shield Biofeedback Technology Assessment Report (TAR) John D. Perry, PhD AAPB Representative

TAR Conclusion

“ … the evidence is not sufficient to demonstrate an additional benefit for biofeedback above that obtained by PME alone.”

Page 7: An Examination of the Blue Cross/Blue Shield Biofeedback Technology Assessment Report (TAR) John D. Perry, PhD AAPB Representative

Is “PME alone” effective?

TAR claims:

“… several controlled trials of PME exist; and collectively these trials establish the effectiveness of PME. (p.4)”

But they cited only two studies:

1. Wells et al 1991 (79% Sx )

2. Burns et al 1993 (54% Sx )

Page 8: An Examination of the Blue Cross/Blue Shield Biofeedback Technology Assessment Report (TAR) John D. Perry, PhD AAPB Representative

1. Wells et al 1991 (79% Sx )

The “PME Alone” group actually included: 7 monthly vaginal palpations (with verbal biofeedback) 7 monthly EMG evaluations

Page 9: An Examination of the Blue Cross/Blue Shield Biofeedback Technology Assessment Report (TAR) John D. Perry, PhD AAPB Representative

2. Burns et al 1993 (54% Sx )

“PME Alone” group actually included two EMG evaluations (pre- and post-treatment) using a biofeedback instrument with an EMG sensor (below)

Page 10: An Examination of the Blue Cross/Blue Shield Biofeedback Technology Assessment Report (TAR) John D. Perry, PhD AAPB Representative

In Contrast, “PME Alone” is far less effective

PME Alone defined as:Verbal instruction only, with no “hands on” biofeedback and no EMG testing

27% Sx

Sampselle et al (March 2000)

Page 11: An Examination of the Blue Cross/Blue Shield Biofeedback Technology Assessment Report (TAR) John D. Perry, PhD AAPB Representative

Stress Inc. = “No Sig. Dif.”

Study OutcomeBFB-PME

Blue CrossReview

Biofeedback Quality Review

Burns 1993

61 – 54% Least Prone to bias

Poor Quality: untrained; PME got 2 EMGs

Berghmans 1996

53 – 60% Least Prone to bias

Poor Quality; stim electrode; PMEs got vag palp. & verbal feedback

Ceresoli1993

62 – 60% PotentialBias

Poor Quality; 6 vs. 13 weeks

Page 12: An Examination of the Blue Cross/Blue Shield Biofeedback Technology Assessment Report (TAR) John D. Perry, PhD AAPB Representative

Stress Inc. = “Sig. Dif. but…”

Study OutcomeBFB–PME

Blue CrossReview

Biofeedback Quality

Burgio1986

80 – 51% Potential Bias

Excellent; but PMEs got vag. Palp. & verbal biofeedback

Glavind1986

91 – 22% Potential Bias

Excellent

Shepherd1983

83 – 25% PotentialBias, no sig. test

Excellent, used home trainers like Kegel

Page 13: An Examination of the Blue Cross/Blue Shield Biofeedback Technology Assessment Report (TAR) John D. Perry, PhD AAPB Representative

Urge Incontinence

• Burton et al, 1988, is cited as finding “no sig. dif.” between BFB and PME alone.

• But Burton called his control group “behavioral treatment”; 11 Urge patients got bladder training and 3 Stress patients got PME instruction. Outcomes are not shown by treatment.

• Burton does not qualify for inclusion in this PME+BFB vs. PME-Alone report.

• A study that should have qualified for inclusion, Burgio 1998, got 81% Symptom Improvement

Page 14: An Examination of the Blue Cross/Blue Shield Biofeedback Technology Assessment Report (TAR) John D. Perry, PhD AAPB Representative

Levels of Pelvic Muscle Exercise

Written instruction

27% Sampselle 2000

Add Vaginal Palpation and verbal feedback

51 - 60% Berghmans 1996; Burgio 1986

Add EMG testing

54 - 77% Burns 1993, Wells 1991

Add formal biofeedback training

80 - 94% Burgio 1998, 1986; Sussett, Kegel, etc.

Page 15: An Examination of the Blue Cross/Blue Shield Biofeedback Technology Assessment Report (TAR) John D. Perry, PhD AAPB Representative

In Historical Perspective

• TAR asks about the benefits of adding Biofeedback to “PME Alone” – but…

• Historically, “PME Alone” results from subtracting Biofeedback from Kegel’s original training program (1948)

Page 16: An Examination of the Blue Cross/Blue Shield Biofeedback Technology Assessment Report (TAR) John D. Perry, PhD AAPB Representative

Historical Origin of PME

Arnold Kegel, the gynecologist who invented PME, conceived and practiced his method as instrument-assisted exercises

1956

Page 17: An Examination of the Blue Cross/Blue Shield Biofeedback Technology Assessment Report (TAR) John D. Perry, PhD AAPB Representative

Kegel’s patients were required to keep records of their

biofeedback results:

Am. J. Obst. & Gynec. 36(2) 1948

Page 18: An Examination of the Blue Cross/Blue Shield Biofeedback Technology Assessment Report (TAR) John D. Perry, PhD AAPB Representative

Summary

• TAR is an evaluation NOT of technology, but of research design

• Examination of even the cited papers contradicts TAR conclusion

• Real-world decisions must be based on the best available evidence

• Biofeedback is “Breakthrough Technology”

Page 19: An Examination of the Blue Cross/Blue Shield Biofeedback Technology Assessment Report (TAR) John D. Perry, PhD AAPB Representative
Page 20: An Examination of the Blue Cross/Blue Shield Biofeedback Technology Assessment Report (TAR) John D. Perry, PhD AAPB Representative

What is Biofeedback’s Added Value?

• Results in 6 weeks, not 6 months

• Increases patient awareness of differences in muscle state

• Ensures that exercises are done correctly

• Provides structure for clinical exercise program

• Provides documentation